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Background: To Investigate whether the g.4760C>T polymorphism in the promoter region of the catalase gene
(CAT) is a risk factor for primary angle closure glaucoma (PACG) in the Saudi population.
Methods: 138 unrelated PACG patients and 403 unrelated control subjects from Saudi Arabia were genotyped for a
single nucleotide polymorphism (SNP; rs1001179; g.4760C>T) utilizing Taq-Man® assay. The association between
different genotypes and various clinical indices important for PACG was also investigated.
Results: The distribution of different genotypes was comparable between both study groups. The genotype “C/C”
was predominant among cafses; 94 (68.1%) and controls; 289 (71.7%). Heterozygous genotype “C/T”, was present in
41 (29.7%) of cases and 103 (25.6%) of controls, where the homozygous variant genotype was present in only 3 (2.2%)
of cases and 11 (2.7%) of the controls. The distribution of variant allele was similar in both study groups (p= 0.568).
Interestingly, there was a trend of association between the type of the variant (homozygous variant, heterozygous
and wildtype genotype) and one important parameter for PACG, which is visual acuity. The visual acuity increase
was; 0.62 (±0.74), 0.88 (±0.88) and 1.27 (±0.95) in patients carrying the “C/C”, “C/T” and “T/T” genotypes respectively,
which was statistically significant in both ANOVA and pairwise individual T tests (p = 0.022, 0.031 and 0.039) when
compared to controls.
Conclusions: This variant is possibly associated with visual acuity in PACG patients and thus had the potential to be
used as a parameter for assessing PACG severity.
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Although glaucoma embodies a heterogeneous group of
optic neuropathies, all types are defined by progressive
and irreversible degeneration of the optic nerve with gradual
visual field loss. Within this group, primary angle-closure
glaucoma (PACG) is a type of glaucoma characterized
by a narrow iridocorneal angle resulting in a blockage of
the aqueous outflow structures. It seems that there is an
anatomical and physiological predisposition to PACG.
Thus, shallow anterior chamber depth is considered an
anatomically inheritable risk factor for this illness [1].* Correspondence: abuamero@gmail.com
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distribution, and reproduction in any mediumCongruently, Eastern Asian ascendance, hyperopia and
female gender significantly predispose to this disease
[2]. It has been estimated that in Saudi Arabia, 40% of
glaucoma patients belong to the PACG type [3]. This
percentage is closer to those calculated for Asian than
for European populations [4]. Although a hereditary com-
ponent for PACG exists, causative genes have not yet been
identified until recently where a significant association
at three new loci: rs11024102 in PLEKHA7 (P=5.33×10
(−12)), rs3753841 in COL11A1 (P=9.22×10(−10)) and
rs1015213 located between PCMTD1 and ST18 on chromo-
some 8q (P=3.29×10(−9)) were reported [5]. The three SNPs
may explain in part some aspects of the PACG pathogen-
esis, but not all. Oxidative stress has been implicated to
cause increased IOP by triggering TM degeneration andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pathway. Indeed, treatment with hydrogen peroxide (H2O2)
impairs TM cell adhesion to the extracellular matrix
and causes rearrangement of cytoskeletal structures [6].
In humans, in vivo experiments demonstrated that oxi-
dative DNA damage is significantly more abundant in
the TM cells of glaucoma patients. Additionally, both
increased IOP and visual field damage were significantly
related to the amount of oxidative DNA damage affect-
ing TM cells [6,7]. Oxidative stress is induced through
formation of excess reactive oxygen species (ROS). Under
normal conditions, ROS is an integral part of signaling
pathways; however, when generated in excess lead to for-
mation of oxidative stress on the cellular environment.
The ROS that damage cellular macromolecules are
scavenged by antioxidant enzymes. Antioxidant enzymes,
such as superoxide dismutase (SOD), catalase and gluta-
thione peroxidase have been reported in aqueous humor
highlighting their importance to maintain a balanced
oxidative status in the eyes. Deficiency or dysfunction of
vascular antioxidant enzymes may result in ROS accu-
mulation and health problem ensues. Levels of antioxi-
dant enzymes play an important role in glaucomatous
disease. Heritable polymorphisms in the antioxidant
enzymes have been evaluated as one of the mechanism
affecting the antioxidant's capacity. Catalase is one of
the key antioxidant enzymes which reduce hydrogen
peroxide to water. Single nucleotide polymorphism (SNP)
(g.4760C>T) in the catalase (CAT) gene (NG_013339.1)
had been shown to lower the catalase activity in the blood
[8]. This SNP had been associated with breast cancer risk
[9]. Recently we showed that this SNP is associated with
three clinical indices important for adult onset primary
open angle glaucoma (POAG) [10]. The aim of the present
study is to evaluate this SNP as a potential risk factor for




The study adheres to the tenets of the Declaration of
Helsinki for research involving humans, and all partici-
pants signed an informed consent a priori. The study
was approved by the College of Medicine Institutional
Research and Ethics Board (approval number # 08–657).
Saudi Arab participants with clinically diagnosed PACG
and healthy controls were both recruited into the study
at King Abdulaziz University Hospital (KAUH) in Riyadh,
Saudi Arabia.
We recruited 138 Saudi PACG patients (cases) who
satisfied strict clinical criteria for PACG which includes
at least three of the following: 1) clinical documentation
of angle closure, defined as the presence of appositional
or synnechial closure of the anterior chamber angleinvolving at least 270 degrees by gonioscopy in either eye;
2) intraocular pressure elevated to a level ≥21 mmHg as
measured by Goldmann applanation tonometry; 3) evi-
dence of characteristic glaucomatous optic disk damage
with excavation of the disc causing a cup-to-disk ratio
(c/d) vertically of at least 0.70 in at least one eye; and
4) characteristic peripheral visual field loss including
nerve fiber bundle defects (nasal step, arcuate scotoma,
paracentral scotoma) or advanced visual field loss (central
and/or temporal island of vision) as tested by Humphrey
Field Analyzer in those patients with vision better than
20/200 or Goldmann Manual Perimetry in those with
worse vision.
Exclusion criteria included: 1) secondary angle closure
glaucoma; 2) presence of pseudoexfoliation syndrome
even if coexistent with angle closure; 3) another cause
of optic nerve injury affecting either eye; 4) significant
visual loss in both eyes not associated with glaucoma;
5) inability to visualize the fundus for optic disk assess-
ment; or 6) refusal to participate.
Patients were recruited from the glaucoma clinic at
King Abdulaziz University Hospital (KAUH) after signing
an informed consent form approved by the institutional
review board (proposal number # 08–657).
A second group (n= 403) of healthy Saudi Arabs con-
trols (Controls group) free from glaucoma by examin-
ation were recruited. Entry criteria for those subjects
were age >40, normal IOP range (≥ 6 and ≤ 21 mmHg),
open angles on gonioscopy, and normal optic nerves on
examination.
DNA preparation
DNA from patients and controls was obtained from
peripheral blood (7 mL) collected in EDTA tubes from
all participating individuals. Extraction was performed
using the illustra blood genomicPrep Mini Spin kit (GE
Healthcare, Buckinghamshire, UK) and stored at −20°C
in aliquots until further use. Quantification of extracted
DNA was performed using a NanoDrop ND-2000c spec-
trophotometer (Thermo Scientific, Wilmington, DE, USA).
Genotyping and validation for SNP rs1001179 of the
CAT gene
Subjects were genotyped to determine the rs1001179 poly-
morphism (g.4760 C>T) in the promoter region of the
CAT gene (NG_013339.1) status using the TaqMan® SNP
Genotyping Assay (Applied Biosystems Inc., Foster City,
CA, USA) on ABI 7500 Real-Time PCR System (Applied
Biosystems). The TaqMan assay uses allele-specific fluoro-
genic probes that, when hybridized to the DNA template
are cleaved by the 5’ nuclease activity of the Taq polymerase
resulting in fluorescence emission from the reporter dye.
Each assay utilizes 2 unlabeled PCR primers and 2 allele-
specific probes and each probe is labeled with a different
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1) and FAM (for allele 2) were used as the reporter dyes.
For detection of rs1001179, assay ID: C_11468118_10 was
used. The reagents were supplied by Applied Biosystems.
Each PCR reaction was performed in a total volume of
25 μL and consisted of 1X TaqMan® Genotyping Master
Mix (Applied Biosystems), 1X SNP Genotyping Assay
Mix and 20 ng DNA. Each 96-well plate included two
no template controls. Real-time PCR was performed on
an ABI 7500 using the recommended conditions consisting
of incubation at 95°C for 10 min, followed by 40 cycles,
denaturation at 92°C for 15 s and annealing/ extension
at 60°C for 1 min. The VIC and FAM fluorescence levels
of the PCR products were measured at 60°C for 1 min.
Analysis of fluorescence using the automated 2-color
allele discrimination software on ABI 7500 showed
clear discrimination of all genotypes of CAT gene on a
two-dimensional graph. Validation of real-time PCR
genotyping results was performed on 10% of randomly
selected samples by sequencing using BigDye terminator
v3.1 cycle sequencing kit (Applied Biosystems). Fragments
were electrophoresed on the ABI 3130xl Genetic Analyzer
(Applied Biosystems) according to the manufacturer’s
protocol. All of the sequenced fragments were then ana-
lyzed using SeqScape software v2.6 (Applied Biosystems).
Statistical analysis
Genotype and clinical indices data of both cases and
controls were collected using a specifically designed data
collection sheet including gene profile as well as all
potentially associated demographic and clinical indices
of patients and controls at presentation. Demographic
data included: subject’s age and sex, while clinical data
included: medical history for co morbidity of systemic
diseases, age at symptoms, duration from onset to presen-
tation, intra-ocular pressure (IOP), cup/disc ratio, Loga-
rithm of the Minimum Angle of Resolution (LogMAR)
visual acuity, and the number of current anti-glaucoma
medications used. A database was built using Microsoft
Access 2007®, where all data were entered, cleaned and
managed.
Data analysis was conducted using SPSS version 19.0
by IBM Inc. (Chicago, IL) and StatsDirect version 2.7.2
by StatsDirect Ltd. (Cheshire, UK). The analysis included
descriptive statistics where continuous variables were
presented as means (±SD) while categorical variables were
presented in forms of frequencies and percentages. In
terms of inferential analysis, odds ratios, 95% confidence
intervals and the corresponding p values were used to
detect the association between different genotypes and
the presence of disease. The student’s T test was used to
compare means across groups as regards continuous
variables, while Mann Whitney U test was alternatively
used whenever indicated. Meanwhile, one way analysisof variance (ANOVA) was used to detect whether there is a
difference in clinical indices at presentation among different
genotypes (alternatively, Kruskal-Wallis Test was used
when indicated). A pairwise t test was also conducted to
detect the source of variation between groups when
detecting a significant difference using the ANOVA find-
ings. During pairwise comparisons, both heterozygous and
homozygous carrying this SNP groups were compared to
the group with the wildtype genotype. A threshold p value
was set to 0.05, where any p value < 0.05 was considered
as statistically significant.
Results
A total of 541 subjects in the age interval of 40 years
and above were recruited for the current study, where
138 subjects with confirmed diagnosis of closed angle
glaucoma were classified as "cases" and 403 other subjects
with confirmed as glaucoma free serving as "controls".
The mean (±SD) age for cases was 63.1 (±9.5) years,
median 64, range [40–87], while that for controls was
61.1 (±10.8) years, median 60 and range [40–93]. Com-
paring both age means, there were no statistically signifi-
cant difference between cases and controls (p = 0.054).
As regards gender, male cases were 84 (60.9%) compared
to 54 (39.1%) females, while in controls, females 282 (70.0%)
were higher in number compared to males 121 (30.0);
(p <0.001). Thirteen (9.4%) patients had a family history
of glaucoma, while 39 (28.3%) were diabetic and 35 (25.4%)
had hypertension. However, only 17 (12.3%) patients
were found to be aware of having glaucoma. Among
the 138 glaucoma cases, 131 (94.8%) were bilateral and
7 (5.2%) were unilateral.
With regard to the distribution of the genotypes, the
wildtype “C/C” was predominant among both cases;
94 (68.1%) and controls; 289 (71.7%). The heterozygous
variant genotype “C/T” was present in 41 (29.7%) of the
cases and 103 (25.6%) of the controls, whereas the
homozygous variant genotype “T/T” was only present in
3 (2.2%) and 11 (2.7%) in cases and controls respectively.
There was no association between having the heterozy-
gous genotype “C/T” and getting closed angle glaucoma;
OR: 1.22 [95% CI: 0.773 - 1.197; p = 0.372] or homozygous
variant “T/T” and having the disease; OR: 0.84 [95% CI:
0.147 – 3.267; p = 0.998]. Additionally, the presence of the
variant allele “T” was the minority among cases 47 (17.0%)
and controls 125 (15.5%) compared to the wild type “C”
allele [229 (83.0%)] and [681 (84.5%)] in cases and controls
respectively, however, the alleles distribution had no
statistically significant association with encountering
the disease; [OR: 1.12 (95% CI: 0.756 – 1.6330), p = 0.568]
(Table 1).
Examining the likelihood of an association between ge-
notypes and important glaucoma clinical indices, showed
that, the mean (±SD) age at onset increased with change
Table 1 Distribution of different genotypes among cases
and controls
Genotype Cases Controls
(n = 138) (n = 403) OR 95% CI P value
No. (%) No. (%)
C/C 94 (68.1) 289 (71.7) - - -
C/T 41 (29.7) 103 (25.6) 1.22 [0.773 – 1.197] 0.372
T/T 3 (2.2) 11 (2.7) 0.84 [0.147 – 3.267] 0.998
Allele
C 229 (83.0) 681 (84.5) - - -
T 47 (17.0) 125 (15.5) 1.12 [0.756 – 1.633] 0.568
All genotypes were in Hardy Weinberg Equilibrium.
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erozygous and heterozygous is worse than wildtype
genotype); 49.0 (±22.7), 57.9 (±12.2) and 62.4 (±8.9)
for “C/C”, “C/T” and “T/T” respectively. This increase was
however, statistically insignificant in ANOVA (p = 0.336).
A similar trend was observed in mean (±SD) duration
between getting closed angle glaucoma and presentation
to the hospital, intraocular pressure (IOP) and logMAR
visual acuity. The visual acuity increase was; 0.62 (±0.74),
0.88 (±0.88) and 1.27 (±0.95) in “C/C”, “C/T” and “T/T”
groups respectively, which was statistically significant in
both ANOVA and pairwise individual T tests (p = 0.022,
0.031 and 0.039). More findings on other clinical indices
at presentation which were not statistically significant
are presented in Table 2.
Discussion
Our interest in studying CAT rs1001179 polymorphism
in the settings of glaucoma stems is due to the following
reasons: First, catalase is an important enzyme for
maintaining the oxidative status of the body and plays a
very important role in protecting the eukaryotic cells
from going into premature apoptosis. Catalase is a
common enzyme found in nearly all living organisms
exposed to oxygen. It catalyzes the decomposition of
hydrogen peroxide to water and oxygen. The CAT geneTable 2 Average clinical indices distributed by different geno
Variable C/C C/T T/T
Mean (±SD) Mean (±SD) Mean (
Age at onset 49.0 (22.7) 57.9 (12.2) 62.4 (8.9
Duration (Months) 43.1 (45.3) 50.4 (41.4) 53.9 (7.0
IOP (mmHg) 18.4 (7.5) 17.6 (7.4) 21.7 (6.8
Visual Acuity (LogMAR) 0.62 (0.74) 0.88 (0.88) 1.27 (0.9
Vertical Cup/Disc ratio 27.7 (35.9) 28.0 (37.0) 25.6 (49
Number of medications 1.59 (1.2) 1.41 (1.0) 1.50 (0.8
LogMAR Logarithm of the Minimum Angle of Resolution.
IOP Intraocular pressure.encodes catalase, a key antioxidant enzyme in the body's
defense against oxidative stress. Catalase is a heme
enzyme that is present in the peroxisome of nearly all
aerobic cells. Catalase converts the ROS hydrogen perox-
ide to water and oxygen and thereby mitigates the toxic
effects of hydrogen peroxide. Oxidative stress is hypothe-
sized to play a role in the development of many chronic or
late-onset diseases such as diabetes, asthma, Alzheimer's
disease, systemic lupus erythematosus, rheumatoid arth-
ritis, and cancers. Polymorphisms in this gene have been
associated with decreases in catalase activity but, to date,
acatalasemia is the only disease known to be caused by
this gene [11,12]. Second, the profound effect of the
g.4760C>T sequence change on the catalase level in the
blood [8]. Third, the increasing evidence of the link be-
tween glaucoma and mitochondrial abnormalities [13]
and the pivotal role mitochondria plays in survival and
maintenance of cellular homeostasis of the RGCs [14].
Fourth, the link between oxidative stress and glaucoma
via the apoptotic events at the RGCs [13]. And lastly,
our recent study had shown that this SNP is associated
with three clinical indices important for adult onset
POAG [10]. Considering all these factors we investigated
the possible association of a SNP (rs1001179) in the pro-
moter of CAT gene with POAG patients of Saudi origin.
To the best of our knowledge, this SNP role in glaucoma
pathogenesis was not previously investigated in the litera-
ture apart from our previous study aforementioned [10].
The results presented in Table 1, indicated that geno-
type frequencies between cases and controls were almost
similar and there was no statistically significant differ-
ence between the two groups. When we investigated the
variant “T” allele frequency in the cases and the controls,
we found no difference (p = 0.568). This indicates that
neither the variant genotype nor the variant allele is a
risk factor for PACG in this population. It’s possible that
the link between mitochondrial abnormalities and/or
oxidative stress and glaucoma are not linked through
the catalase pathway and that other oxidative stress
pathway(s) may be involved. In any case, the exacttypes
All cases Anova p value T test p value
±SD) Mean (±SD) (All groups) CT/CC TT/CC
) 52.9 (18.8) 0.336 0.336 0.351
) 46.7 (42.9) 0.645 0.645 0.690
) 18.2 (7.5) 0.397 0.447 0.302
5) 0.71 (0.80) 0.022 0.031 0.039
.6) 27.7 (36.2) 0.991 0.957 0.906
) 1.50 (1.2) 0.647 0.356 0.854
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glaucoma pathogenesis remains speculative. Additionally,
glaucomatous optic neuropathy implies loss of RGCs,
including their axons, and a major tissue remodeling,
especially in the optic nerve head. Mechanisms leading
to glaucomatous optic neuropathy are not yet clearly
understood. We previously investigated mitochondrial
abnormalities in a group of patients with PACG and
found absence of mitochondrial abnormalities in those
patients [15]. We suggested at the time that optic nerve
injury in PACG has been attributed primarily to ele-
vated IOP caused by anatomic changes in the anterior
and posterior globe [16], in contrast with the molecular
and biochemical abnormalities suspected in POAG [17].
Interestingly, when we investigated the potential asso-
ciation between the presence of a certain genotype and
different clinical indices, important for PACG, we found
an interesting trend corresponding to various clinical
indices and severity of the variant (i.e. Homozygous
variant, followed by heterozygous, and the least severe
is the wildtype). The mean (±SD) age at onset increased
with increase in variation severity (homozygous variant
is worst than heterozygous and heterozygous is worst
than wildtype), but statistically insignificant. On the
other hand, the visual acuity increase was; 0.62 (±0.74),
0.88 (±0.88) and 1.27 (±0.95) in “C/C”, “C/T” and “T/T”
groups respectively, which was statistically significant in
both ANOVA and individual T tests (p = 0. 022, 0.031
and 0.039 respectively). Other clinical indices listed in
Table 2 were not associated with the genotypes investigated.
There are few limitations to this study: i) the study
was conducted on the Saudi population only and thus
need to be carried out in other populations to establish
the link between this variant and various clinical indices;
2) at this point, modifiers for this catalase SNP leading
to glaucoma are not known and thus we will not know
for sure if this SNP alone can influence the disease se-
verity; 3) We cannot exclude other SNPs at the same
locus, which may be associated with POAG and 4) Con-
sidering the fact that the frequency of the homozygous
(T/T) variants was low (3/138; 2.2% in cases and 11/403;
2.7% in controls) it is also plausible that more individuals
are needed for such case–control genetic association
study.
Conclusion
In summary, we showed a possible association of the
catalase polymorphism (g.4760 C>T) with the visual
acuity, which is an important clinical indices for PACG.
Thus, this SNP can be potentially used as a marker for
PACG severity.
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